HanchorBio Announces U.S. FDA Clearance of IND Application for HCB303, a Next-Generation Trispecific Immunotherapy

RegulatoryapprovedHCB303Positive

AI Analysis

Summary

HanchorBio announced FDA IND clearance for HCB303, a next-generation trispecific immunotherapy targeting TIGIT, PD-L1, and CD47 for advanced solid tumors. The company plans to initiate a Phase 1 first-in-human dose-escalation trial.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA IND clearance granted

Importance:6/10

Sentiment:

0.80

immunotherapytrispecificTIGITPD-L1CD47IND clearancefirst-in-human

Related Companies

$GBIO $ICPT $RHEPB $SLDB $TRAX

Read the original article

Published by PR Newswire Biotech on October 5, 2026 10:00 AM

Read Original